Pablo E Vivas-Mejia

Title: Innovations of Pablo E Vivas-Mejia

Introduction

Pablo E Vivas-Mejia is a notable inventor based in San Juan, Puerto Rico. He has made significant contributions to the field of cancer research, particularly in developing innovative therapeutic strategies for treating cisplatin-resistant ovarian cancer. With a total of three patents to his name, Vivas-Mejia's work is paving the way for new treatment options in oncology.

Latest Patents

One of his latest patents is titled "Nanoliposomal c-MYC-siRNA inhibits in vivo tumor growth of cisplatin-resistant ovarian cancer." This invention discloses a c-MYC-siRNA formulation as a potential therapeutic target for cisplatin-resistant ovarian cancer. The patent details how targeting c-MYC with small interfering RNA (siRNA) in the cisplatin-resistant ovarian cancer cell line induces significant cell growth arrest and inhibits cell proliferation. Furthermore, apoptosis and arrest of cell cycle progression were observed after c-MYC-siRNA-based silencing of c-MYC. The delivery of nanoliposomal c-MYC-siRNA resulted in decreased tumor weight and a reduced number of tumor nodules compared to a liposomal-negative control siRNA.

Career Highlights

Throughout his career, Vivas-Mejia has focused on innovative approaches to cancer treatment. His research has garnered attention for its potential to improve outcomes for patients with resistant forms of cancer. His dedication to advancing medical science is evident in his patent filings and ongoing research efforts.

Collaborations

Vivas-Mejia has collaborated with notable colleagues in his field, including Jeyshka M Reyes Gonzalez and Anil K Sood. These collaborations have likely contributed to the depth and impact of his research.

Conclusion

Pablo E Vivas-Mejia is an influential inventor whose work in cancer research is making strides toward effective treatments for challenging conditions. His innovative patents reflect a commitment to improving patient care and advancing medical science.